Journey Medical expands Emrosi payer coverage to 65% of commercial lives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
July 14, 2025 8:30 AM EDTPayer coverage for Emrosi now available for 65% of commercial lives, up from 29% in May 2025
Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase
SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (Journey Medical or the Company, we, or our), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi (40 mg Minocycline... More
